The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis ...
Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...
GlobalData on MSN23h
Genentech eyes lupus market for Gazyva with positive Phase III data readoutRoche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company targets the billion-dollar lupus market for its CD20-targeting drug Gazyva ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback